Literature DB >> 27612365

Effect of Stellate Ganglion Block on Specific Symptom Clusters for Treatment of Post-Traumatic Stress Disorder.

James H Lynch1, Sean W Mulvaney2, Eugene H Kim3, Jason B de Leeuw4, Matthew J Schroeder5, Shawn F Kane6.   

Abstract

This study assessed which symptoms are most impacted following stellate ganglion block (SGB) used to treat post-traumatic stress disorder (PTSD) symptoms. 30 active military service members with combat-related PTSD self-referred to their physician and psychologist. Patients were offered a SGB as part of their treatment program. Primary outcome was the magnitude of change for the 17 items on the PTSD Checklist-Military (PCL-M), which was administered the week before SGB, 1 week after SGB, and 2 to 4 months later. Mean PCL-M score decreased from 49 at baseline to 32, 1 week after the procedure (p < 0.001). 2 to 4 months after SGB, patients maintained an average PCL-M of 32. Patients reported greatest improvement in the first week after SGB for the following symptoms: irritability or angry outbursts, difficulty concentrating, and sleep disturbance. 2 to 4 months later, patients reported greatest improvement in the following: feeling distant or cut off, feeling emotionally numb, irritability or angry outbursts, and difficulty concentrating. SGB is a safe procedure that may provide extended relief for all clusters of PTSD symptoms. As a result of the significant reduction in hyperarousal and avoidance symptoms observed, this study supports incorporation of SGB into PTSD treatment plans. Reprint &
Copyright © 2016 Association of Military Surgeons of the U.S.

Entities:  

Mesh:

Year:  2016        PMID: 27612365     DOI: 10.7205/MILMED-D-15-00518

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  8 in total

1.  Effects of ultrasound-guided stellate-ganglion block on sleep and regional cerebral oxygen saturation in patients undergoing breast cancer surgery: a randomized, controlled, double-blinded trial.

Authors:  Feng Jin; Xiao-Qian Li; Wen-Fei Tan; Hong Ma; Bo Fang; A-Yong Tian; Huang-Wei Lu
Journal:  J Clin Monit Comput       Date:  2017-10-17       Impact factor: 2.502

2.  Transition from Deep Regional Blocks toward Deep Nerve Hydrodissection in the Upper Body and Torso: Method Description and Results from a Retrospective Chart Review of the Analgesic Effect of 5% Dextrose Water as the Primary Hydrodissection Injectate to Enhance Safety.

Authors:  Stanley K H Lam; Kenneth Dean Reeves; An-Lin Cheng
Journal:  Biomed Res Int       Date:  2017-10-01       Impact factor: 3.411

3.  Treatment of multiple physiological and psychological disorders in one patient with stellate ganglion block: a case report.

Authors:  Yunyao Xu; Yuenong Zhang
Journal:  J Int Med Res       Date:  2021-01       Impact factor: 1.671

Review 4.  Stellate Ganglion Block for Psychiatric Disorders: A Systematic Review of the Clinical Research Landscape.

Authors:  Jaimie Kerzner; Helen Liu; Ilya Demchenko; David Sussman; Duminda N Wijeysundera; Sidney H Kennedy; Karim S Ladha; Venkat Bhat
Journal:  Chronic Stress (Thousand Oaks)       Date:  2021-12-08

5.  Case Series: Cancer-Related Facial Pain Treated with Stellate Ganglion Block.

Authors:  Raheleh Rahimi Darabad; Jerry P Kalangara; Anna Woodbury
Journal:  Palliat Med Rep       Date:  2020-12-02

6.  Stellate ganglion block treats posttraumatic stress: An example of precision mental health.

Authors:  James H Lynch
Journal:  Brain Behav       Date:  2020-08-28       Impact factor: 2.708

7.  Real-time ultrasound-guided stellate ganglion block for migraine: an observational study.

Authors:  Zhiqiang Lu; Junzhen Wu; Jiawei Hou; Shaofeng Pu; Xingguo Xu
Journal:  BMC Anesthesiol       Date:  2022-03-24       Impact factor: 2.217

8.  Behavioral health clinicians endorse stellate ganglion block as a valuable intervention in the treatment of trauma-related disorders.

Authors:  James H Lynch; Peter D Muench; John C Okiishi; Gary E Means; Sean W Mulvaney
Journal:  J Investig Med       Date:  2021-03-16       Impact factor: 2.895

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.